Buronil (Melperone)
Atypical antipsychotic — butyrophenone derivative for sleep disorders and psychomotor agitation
Buronil is the brand name for melperone, a low-potency atypical antipsychotic belonging to the butyrophenone class. It is primarily prescribed for the short-term treatment of sleep disorders, psychomotor agitation, and restlessness, particularly in elderly patients where benzodiazepines may be inappropriate. Melperone is distinguished from other antipsychotics by its relatively favorable side-effect profile, with a notably low incidence of extrapyramidal symptoms.
Quick Facts: Buronil
Key Takeaways
- Buronil (melperone) is a low-potency antipsychotic primarily used for sleep disturbances and psychomotor agitation, especially in elderly patients.
- It has a lower risk of extrapyramidal side effects compared to typical antipsychotics like haloperidol, making it better tolerated in geriatric populations.
- The usual dose for insomnia is 25–50 mg taken at bedtime; higher doses (up to 200–400 mg daily) may be used for psychotic symptoms under close medical supervision.
- Common side effects include drowsiness, fatigue, dizziness, and orthostatic hypotension — patients should be cautioned about fall risk.
- All antipsychotics, including melperone, carry warnings regarding increased mortality in elderly patients with dementia-related psychosis.
What Is Buronil and What Is It Used For?
Quick Answer: Buronil contains the active substance melperone, a butyrophenone-type antipsychotic. It is primarily used for the short-term treatment of insomnia, psychomotor agitation, and restlessness, particularly when benzodiazepines are not suitable. Melperone has sedative properties with a relatively low risk of movement-related side effects.
Buronil (melperone hydrochloride) is classified as a low-potency atypical antipsychotic medication that belongs to the butyrophenone chemical family — the same class as haloperidol, though with markedly different pharmacological properties. Melperone was first synthesized in the 1960s and has been in clinical use in several European countries for decades. While it is not as widely known globally as newer atypical antipsychotics such as quetiapine or olanzapine, melperone occupies an important therapeutic niche in European psychiatry and geriatric medicine.
The primary mechanism of action of melperone involves antagonism at dopamine D2 receptors in the central nervous system, combined with significant serotonin 5-HT2A receptor blocking activity. This dual receptor profile is what gives melperone its classification as an atypical antipsychotic, despite being a butyrophenone. Additionally, melperone exerts notable antagonism at histamine H1 receptors, which accounts for much of its sedative and sleep-promoting effects. Unlike many other antipsychotics, melperone has relatively weak activity at muscarinic acetylcholine receptors, which means it causes fewer anticholinergic side effects such as dry mouth, blurred vision, and urinary retention compared to agents like chlorpromazine.
Clinically, Buronil is prescribed for a range of indications, though the specific licensed indications may vary by country. The most common therapeutic uses include:
- Sleep disorders (insomnia): Melperone is widely used as a non-benzodiazepine hypnotic, particularly for patients in whom benzodiazepines are contraindicated or where there is concern about dependency. At low doses (25–50 mg), it promotes sleep onset and improves sleep maintenance without the rebound insomnia and dependency issues associated with benzodiazepine hypnotics.
- Psychomotor agitation and restlessness: In moderate doses, melperone is effective in managing agitated states, particularly in elderly patients with dementia or delirium. It helps reduce restlessness without causing excessive sedation at appropriate doses.
- Alcohol withdrawal: Melperone has been used as an adjunctive treatment during alcohol detoxification, where its sedative properties help manage withdrawal-related anxiety and agitation.
- Schizophrenia and psychotic disorders: At higher doses (200–400 mg daily), melperone can be used as an antipsychotic for the management of schizophrenia and related disorders, although this is less common than its use for insomnia and agitation.
- Behavioral and psychological symptoms of dementia (BPSD): Melperone is sometimes prescribed for agitation, aggression, and sleep disturbance in patients with Alzheimer's disease and other dementias, though this must be weighed against the known risks of antipsychotic use in this population.
Melperone is rapidly absorbed from the gastrointestinal tract after oral administration, reaching peak plasma concentrations within approximately 1 to 2 hours. It is metabolized primarily in the liver via the cytochrome P450 enzyme CYP2D6, and its elimination half-life ranges from approximately 6 to 8 hours. This relatively short half-life means that the sedative effects typically wear off by morning when the drug is taken at bedtime, reducing daytime hangover effects compared to some longer-acting sedatives.
What Should You Know Before Taking Buronil?
Quick Answer: Before starting Buronil, inform your doctor about all medical conditions (especially heart disease, liver problems, Parkinson's disease, or epilepsy), current medications, and whether you are pregnant or breastfeeding. Buronil should not be used in patients with known hypersensitivity to melperone, pheochromocytoma, or severe CNS depression.
Contraindications
There are several important contraindications for Buronil that must be considered before prescribing. Melperone should not be used in patients who have a known hypersensitivity to melperone hydrochloride or any of the excipients contained in the formulation. Other absolute contraindications include severe central nervous system depression from any cause, including acute intoxication with alcohol, opioids, or other CNS depressants. Patients with pheochromocytoma (a rare adrenal gland tumor) should not take melperone, as all dopamine antagonists can provoke a hypertensive crisis in these patients.
Melperone should also be avoided in patients with prolactin-dependent tumors, as dopamine blockade can increase prolactin levels. Patients with known QT prolongation syndrome or those taking other medications that significantly prolong the QT interval should use melperone only under careful cardiac monitoring, as there is a dose-dependent risk of QT prolongation.
Warnings and Precautions
Several important warnings apply to the use of Buronil. Healthcare providers should exercise particular caution when prescribing melperone in the following situations:
- Elderly patients with dementia: All antipsychotic medications, including melperone, are associated with an increased risk of cerebrovascular events (stroke) and overall mortality when used in elderly patients with dementia-related psychosis. This risk applies to both typical and atypical antipsychotics. The use of Buronil in this population must be carefully justified and regularly reassessed.
- Cardiovascular disease: Melperone can cause orthostatic hypotension (a drop in blood pressure upon standing), which may be problematic in patients with cardiovascular disease, cerebrovascular disease, or conditions predisposing to hypotension such as dehydration or concurrent use of antihypertensive medications.
- Hepatic impairment: Since melperone is metabolized by the liver, patients with significant hepatic dysfunction may experience increased drug levels and enhanced effects. Dose adjustments may be necessary in patients with liver disease.
- Parkinson's disease: Melperone, like all dopamine antagonists, can worsen the motor symptoms of Parkinson's disease. It should generally be avoided in patients with Parkinson's disease or Lewy body dementia.
- Epilepsy: Antipsychotics, including melperone, can lower the seizure threshold. Patients with epilepsy or a history of seizures should be monitored carefully, and anticonvulsant therapy may need adjustment.
- Neuroleptic malignant syndrome (NMS): Although rare, this potentially life-threatening condition can occur with any antipsychotic medication. Symptoms include high fever, muscle rigidity, altered consciousness, and autonomic instability. Buronil should be discontinued immediately if NMS is suspected.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Buronil is not approved for the treatment of dementia-related psychosis. Discuss the risks and benefits carefully with your prescribing physician.
Pregnancy and Breastfeeding
The use of Buronil during pregnancy has not been extensively studied in controlled clinical trials. Animal studies have not shown clear evidence of teratogenicity, but as with all medications, the potential risks to the fetus must be weighed against the benefits to the mother. Melperone should only be used during pregnancy if the expected benefit clearly outweighs the potential risk to the developing baby.
If antipsychotic medications, including melperone, are used during the third trimester of pregnancy, neonates may experience extrapyramidal symptoms and withdrawal symptoms after delivery. These symptoms may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, respiratory distress, and feeding problems. The severity of these symptoms can range from self-limiting to potentially requiring intensive care and prolonged hospitalization.
Melperone may pass into breast milk, and its effects on the nursing infant have not been adequately studied. Therefore, a decision must be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. If breastfeeding is continued while taking melperone, the infant should be monitored for signs of sedation, poor feeding, and developmental concerns.
How Does Buronil Interact with Other Drugs?
Quick Answer: Buronil can interact with alcohol, CNS depressants, levodopa, QT-prolonging drugs, and medications metabolized by the CYP2D6 enzyme system. Always inform your doctor about all medications, supplements, and herbal products you are taking before starting Buronil.
Drug interactions are an important consideration when using melperone, particularly in elderly patients who often take multiple medications concurrently. The pharmacological properties of melperone — its CNS-depressant effects, dopamine antagonism, and hepatic metabolism — create several potential interaction pathways that clinicians and patients should be aware of.
Major Interactions
Certain drug combinations with melperone carry significant clinical risk and should generally be avoided or used only under close medical supervision:
| Interacting Drug/Class | Effect | Clinical Significance |
|---|---|---|
| Alcohol | Enhanced CNS depression, increased sedation | Avoid concurrent use. Risk of respiratory depression, severe hypotension, and excessive sedation. |
| Levodopa / Dopamine agonists | Mutual antagonism of therapeutic effects | Melperone blocks dopamine receptors, potentially counteracting the effects of Parkinson's medications. |
| QT-prolonging drugs (e.g., amiodarone, sotalol, erythromycin, certain antidepressants) | Additive QT prolongation | Increased risk of serious cardiac arrhythmias including torsades de pointes. ECG monitoring required. |
| CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion) | Increased melperone plasma levels | May require dose reduction of melperone. Monitor for increased side effects. |
| Benzodiazepines / Opioids | Additive CNS depression | Risk of excessive sedation, respiratory depression, and falls. Use lowest effective doses. |
Minor Interactions
Several medications may interact with melperone in ways that are generally manageable with appropriate monitoring and dose adjustments:
- Antihypertensive medications: Melperone can potentiate the blood pressure-lowering effects of antihypertensive drugs, increasing the risk of orthostatic hypotension. Blood pressure should be monitored when initiating or adjusting doses of either medication.
- Anticholinergic drugs: Although melperone has relatively weak anticholinergic activity, the combination with strongly anticholinergic medications may result in additive effects such as dry mouth, constipation, and urinary retention.
- Lithium: Concurrent use of lithium with antipsychotics may rarely increase the risk of neurotoxicity. Monitor for signs such as confusion, fever, tremor, and extrapyramidal symptoms.
- Herbal supplements (St. John's Wort): St. John's Wort is a known CYP enzyme inducer and may decrease melperone plasma levels, potentially reducing its effectiveness.
Always bring a complete list of all your medications, including over-the-counter drugs and supplements, to every medical appointment. Drug interactions can be complex, and your healthcare provider needs full information to prescribe safely. Even seemingly harmless supplements like grapefruit juice can affect drug metabolism.
What Is the Correct Dosage of Buronil?
Quick Answer: The dosage of Buronil depends on the indication. For insomnia, the typical adult dose is 25–50 mg at bedtime. For agitation, doses of 25–100 mg divided throughout the day may be prescribed. For psychotic disorders, higher doses up to 200–400 mg daily may be required. Always follow your prescriber's instructions.
Dosing of Buronil (melperone) must be individualized based on the patient's clinical condition, age, weight, concurrent medications, and response to treatment. The general principle with antipsychotics is to start at the lowest effective dose and titrate upward gradually as needed, particularly in elderly patients who are more susceptible to adverse effects. The following dosage guidelines represent common clinical practice, though prescribers should always refer to the most current product information in their jurisdiction.
Adults
Insomnia / Sleep Disorders
25–50 mg taken orally, 30–60 minutes before bedtime. In some cases, the dose may be increased to 100 mg if the lower dose is insufficient, although this should be done cautiously and only after adequate trial of the lower dose. Treatment duration for insomnia should be as short as possible, with regular reassessment of the need for continued therapy.
Psychomotor Agitation / Restlessness
25–100 mg per day, divided into 2–3 doses. The dose should be titrated based on clinical response. The majority of patients respond to doses in the range of 50–150 mg daily.
Psychotic Disorders (Schizophrenia)
200–400 mg per day in divided doses. Treatment should begin at a lower dose (e.g., 50–100 mg/day) and be gradually increased over several days to weeks. The maximum recommended daily dose is generally 400 mg, though some references cite higher doses under specialist supervision.
Children
Buronil is generally not recommended for children and adolescents under 18 years of age due to insufficient data on safety and efficacy in this population. The use of antipsychotics in children requires specialist psychiatric assessment and should only occur when the potential benefits clearly outweigh the risks. If melperone is considered for a pediatric patient in exceptional circumstances, dosing must be determined by a specialist on an individual basis.
Elderly
Geriatric Dosing
Elderly patients should start at the lowest possible dose, typically 25 mg at bedtime for insomnia. Dose increases should be made slowly and cautiously, with careful monitoring for orthostatic hypotension, excessive sedation, and fall risk. In elderly patients, the maximum daily dose should generally not exceed 100–150 mg. Regular reassessment (at least every 3 months) is essential, with the goal of tapering and discontinuing the medication when clinically appropriate.
Missed Dose
If you miss a dose of Buronil, take it as soon as you remember unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. If Buronil is prescribed for insomnia and you forget to take it before bedtime, do not take it later during the night, as this may cause excessive daytime drowsiness the following day.
Overdose
An overdose of melperone can be life-threatening. Symptoms of overdose may include severe drowsiness or loss of consciousness, marked hypotension, tachycardia or bradycardia, respiratory depression, hypothermia, seizures, and cardiac arrhythmias (including QT prolongation and torsades de pointes). In severe cases, coma and death can occur.
If overdose is suspected, call your local poison control center or emergency services immediately. Treatment is supportive and symptomatic, as there is no specific antidote for melperone. Gastric lavage may be considered if the patient presents within one hour of ingestion. Continuous cardiac monitoring and supportive care in an intensive care setting may be required.
What Are the Side Effects of Buronil?
Quick Answer: The most common side effects of Buronil include drowsiness, fatigue, dizziness, and nasal congestion. Orthostatic hypotension (feeling lightheaded when standing up) can occur, especially at higher doses. Extrapyramidal symptoms are uncommon compared to typical antipsychotics. Report any unusual symptoms to your healthcare provider.
Like all medications, Buronil (melperone) can cause side effects, although not everybody experiences them. One of the distinguishing features of melperone compared to other butyrophenone antipsychotics is its relatively favorable side-effect profile, particularly with regard to movement disorders (extrapyramidal symptoms). This is attributed to its balanced dopamine D2 and serotonin 5-HT2A receptor antagonism, which gives it pharmacological properties more similar to atypical antipsychotics despite being a butyrophenone.
The following side effects are organized by frequency according to standard MedDRA (Medical Dictionary for Regulatory Activities) frequency categories based on available clinical data and post-marketing surveillance reports:
Very Common (affects more than 1 in 10 people)
Frequency: >10%
- Drowsiness / sedation (dose-dependent, most pronounced in the first days of treatment)
- Fatigue and tiredness
Common (affects 1 to 10 in 100 people)
Frequency: 1–10%
- Dizziness and lightheadedness
- Orthostatic hypotension (drop in blood pressure when standing)
- Nasal congestion
- Dry mouth
- Headache
- Constipation
- Weight gain (with prolonged use)
Uncommon (affects 1 to 10 in 1,000 people)
Frequency: 0.1–1%
- Extrapyramidal symptoms (tremor, stiffness, restlessness)
- Skin rashes or hypersensitivity reactions
- Nausea or gastrointestinal discomfort
- Tachycardia (rapid heartbeat)
- Elevated prolactin levels
- Sexual dysfunction
- Blurred vision
Rare (affects fewer than 1 in 1,000 people)
Frequency: <0.1%
- Neuroleptic malignant syndrome (NMS) — a medical emergency
- QT prolongation and cardiac arrhythmias
- Tardive dyskinesia (involuntary movements, typically with long-term high-dose use)
- Blood dyscrasias (changes in blood cell counts)
- Liver function abnormalities
- Seizures (lowered seizure threshold)
- Venous thromboembolism (deep vein thrombosis, pulmonary embolism)
It is important to note that the severity and incidence of side effects are dose-dependent. At the low doses used for insomnia (25–50 mg), the most commonly experienced side effects are drowsiness and mild dizziness, which are generally well tolerated and often diminish over the first few days of treatment. At higher antipsychotic doses (200–400 mg daily), the risk and severity of all listed side effects increase accordingly.
Patients should be advised to report any unexpected or troublesome symptoms to their healthcare provider. In particular, seek immediate medical attention if you experience symptoms suggestive of neuroleptic malignant syndrome (high fever, severe muscle rigidity, confusion, rapid heartbeat), signs of blood clots (swelling, redness, or pain in a leg; sudden shortness of breath or chest pain), or unusual involuntary movements.
How Should You Store Buronil?
Quick Answer: Store Buronil at room temperature (below 25°C / 77°F) in the original packaging, protected from light and moisture. Keep out of the reach and sight of children. Do not use after the expiry date printed on the packaging.
Proper storage of medications is essential to ensure they remain effective and safe throughout their shelf life. Buronil (melperone) tablets should be stored according to the following guidelines:
- Temperature: Store at room temperature, not exceeding 25°C (77°F). Do not refrigerate or freeze the tablets.
- Light protection: Keep the tablets in the original blister pack or container to protect them from direct sunlight and excessive light exposure.
- Moisture protection: Store in a dry place. Avoid keeping the medication in the bathroom or other humid environments, as moisture can degrade the tablet coating and affect the drug's stability.
- Child safety: Keep all medications out of the reach and sight of children. Consider using a lockable medicine cabinet, particularly in households with young children.
- Expiry date: Do not use Buronil after the expiry date stated on the blister pack and outer carton. The expiry date refers to the last day of that month.
Do not dispose of unused or expired medications in household waste or down the drain. Return any leftover tablets to your local pharmacy for safe disposal in accordance with local regulations. Many pharmacies and healthcare facilities operate medication take-back programs for this purpose. Proper disposal of unused medications helps protect the environment and prevents accidental ingestion by children, pets, or others.
What Does Buronil Contain?
Quick Answer: Each Buronil film-coated tablet contains 25 mg of melperone hydrochloride as the active ingredient, along with inactive excipients including lactose monohydrate, maize starch, and various coating agents.
Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific pharmaceutical ingredients. Each Buronil 25 mg film-coated tablet contains the following components:
Active Ingredient
Melperone hydrochloride 25 mg (equivalent to approximately 21.6 mg melperone base). Melperone is a butyrophenone derivative with the chemical formula C16H22FNO·HCl and a molecular weight of 299.81 g/mol. It is a white to off-white crystalline powder that is freely soluble in water.
Inactive Ingredients (Excipients)
The inactive ingredients in the tablet formulation may include:
- Tablet core: Lactose monohydrate, maize starch (corn starch), microcrystalline cellulose, povidone, magnesium stearate, and colloidal anhydrous silica.
- Film coating: Hypromellose (hydroxypropyl methylcellulose), titanium dioxide (E171), macrogol (polyethylene glycol), and iron oxide yellow (E172) for coloring.
Buronil tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
The film-coated tablets are typically round, biconvex in shape, and may be scored to facilitate dose splitting when lower doses are required. The specific appearance of the tablet may vary depending on the manufacturer and market.
Frequently Asked Questions About Buronil
Medical References & Sources
All information in this article is based on peer-reviewed medical literature, international prescribing guidelines, and regulatory authority documents. Evidence level: 1A (systematic reviews and controlled clinical trials).
- European Medicines Agency (EMA). "Summary of Product Characteristics: Melperone." European Public Assessment Reports. Official European regulatory information for melperone-containing products.
- World Health Organization (WHO). "WHO Model List of Essential Medicines — 23rd List, 2023." WHO Technical Report Series. International reference for essential medications and prescribing standards.
- British National Formulary (BNF). "Antipsychotic Drugs: Prescribing Guidelines." NICE Evidence Services, 2024. Comprehensive UK prescribing guidelines for antipsychotic medications.
- Stahl SM. (2021). "Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications." 5th Edition. Cambridge University Press. Comprehensive textbook on psychopharmacology, including butyrophenone antipsychotics.
- Maudsley Prescribing Guidelines in Psychiatry. (2024). 15th Edition. Taylor DM, Barnes TRE, Young AH. Wiley-Blackwell. Authoritative evidence-based prescribing guidelines for psychiatric medications.
- Leucht S, et al. (2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis." The Lancet. 382(9896):951-962. Landmark meta-analysis comparing antipsychotic efficacy and tolerability.
- Schneider LS, et al. (2005). "Risk of death with atypical antipsychotic drug treatment for dementia." JAMA. 294(15):1934-1943. Key study on antipsychotic mortality risk in elderly dementia patients.
- Ihl R, et al. (2012). "The use of melperone in elderly patients with sleep disorders, agitation, and delirium." International Journal of Geriatric Psychiatry. Clinical study on melperone use in geriatric populations.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog. Read more
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in psychiatry, pharmacology, geriatric medicine, and clinical pharmacy.